Video

State-of-the-Art Management of High-Risk Non-Muscle Invasive Bladder Cancer VL

Advances Bring Immunotherapy and Targeted Therapy Options for Non-Muscle Invasive Bladder Cancer - Kriti Mittal & Guru Sonpavde Details Kriti Mittal and Guru Sonpavde discuss advancements in the treatment of non-muscle invasive bladder cancer. Dr. Mittal highlights the FDA's 2020 approval of pembrolizumab for high-risk, BCG-unresponsive cases, based on the KEYNOTE-057 study. This study demonstrated a notable clinical response at three and twelve months. Atezolizumab, although showing some response, didn't meet its threshold in a s...
Inside the 92nd AUA Meeting: A Deep Dive into High-Risk Non-Muscle Invasive Bladder Cancer - Kriti Mittal Details During the State-of-the-Art Management of High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) multidisciplinary symposium held at the 2023 Meeting of the New England Section of the AUA Kriti Mittal opens the symposium organized in partnership with the Bladder Cancer Advocacy Network and supported by Pfizer, the event features a panel of experts from various institutions. This video is part of the...
The Complex Case of a 46-Year-Old Smoker with High-Grade T1 Bladder Cancer Presentation - Jennifer Yates, Matthew Mossanen, & Kent Mouw Details During the State-of-the-Art Management of High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) multidisciplinary symposium held at the 2023 Meeting of the New England Section of the AUA Matthew Mossanen presents a case study of a 46-year-old patient with a history of heavy smoking and other comorbidities. The patient underwent treatment with cisplatin and etoposide, followed by imaging and an even...
In the Wake of BCG Shortages: A Look at Ongoing Clinical Trials and Future Therapies for Bladder Cancer - Jennifer Yates, Lydia Saravis, & Matthew Mossanen Details During the State-of-the-Art Management of High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) multidisciplinary symposium held at the 2023 Meeting of the New England Section of the AUA Matthew Mossanen led a detailed discussion and experts delved into the complexities of treating high-risk non-muscle invasive bladder cancer, focusing on BCG-unresponsive and BCG-refractory cases. Dr. Mossanen pres...
The Future of Radiation and Anti-PD-1 Agents in Non-Muscle Invasive Bladder Cancer: An In-Depth Look at Ongoing Trials - Kent Mouw Details During the State-of-the-Art Management of High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) multidisciplinary symposium held at the 2023 Meeting of the New England Section of the AUA Kent Mouw discusses the evolving role of radiation in treating non-muscle invasive bladder cancer, emphasizing that there's no standard role for definitive radiation yet. He presents data from various trials, inclu...
Persistent CIS Despite BCG and Valrubicin: A Case Study in Treatment Challenges - Kriti Mittal Details During the State-of-the-Art Management of High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) multidisciplinary symposium held at the 2023 Meeting of the New England Section of the AUA Kriti Mittal presents the case of a 74-year-old male with persistent high-grade urothelial carcinoma in-situ (CIS) despite multiple treatments, including BCG, valrubicin, and pembrolizumab. She transitions into dis...
A Comprehensive Guide to Managing Immune-Related Adverse Events in Checkpoint Inhibitor Therapy - Laura Wood Details During the State-of-the-Art Management of High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) multidisciplinary symposium held at the 2023 Meeting of the New England Section of the AUA Laura Wood delves into the complexities of managing immune-related adverse events (irAEs) in patients undergoing checkpoint inhibitor therapy. She emphasizes the importance of early identification and effective man...
An Overview of Emerging Agents for Non-Muscle Invasive Bladder Cancer - Guru Sonpavde Details During the State-of-the-Art Management of High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) multidisciplinary symposium held at the 2023 Meeting of the New England Section of the AUA Guru Sonpavde provides a comprehensive overview of emerging agents for non-muscle invasive bladder cancer, highlighting both successes and challenges. He discusses a small phase one trial of intravesical pembrolizu...

State-of-the-Art Management of High-Risk Non-Muscle Invasive Bladder Cancer VL

Login